Search research articles
Contact Us
Filters
Showing results (71-80 of 116) with videos related to
Page
of 12
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
November 1, 2013
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Jürgen Geisler, Ingeborg M Bachmann, Marta Nyakas, et al.
Oncotarget
|
December 2, 2015
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
Hui-Wen Lue, Brook Cole, Soumya A M Rao, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
Thomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies
Stephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood
|
September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Thomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Cold Spring Harbor Molecular Case Studies
|
October 28, 2022
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia
Mara W Rosenberg, Samantha L Savage, Christopher A Eide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I
Julia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Cancer Research
|
April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile
Christopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Nature Genetics
|
December 22, 2005
Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction
Helge Raeder, Stefan Johansson, Pål I Holm, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|
February 3, 2026
International validation of a staging system for ciliary body and choroidal melanomas using estimated tumour volume
Sacha Nahon-Estève, Jean-Pierre Caujolle, Célia Maschi, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 116) with videos related to
Sort By:
Page
of 12
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
November 1, 2013
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Jürgen Geisler, Ingeborg M Bachmann, Marta Nyakas, et al.
Oncotarget
|
December 2, 2015
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma
Hui-Wen Lue, Brook Cole, Soumya A M Rao, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 28, 2008
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib
Thomas O'Hare, Christopher A Eide, Jeffrey W Tyner, et al.
Biorxiv : the Preprint Server for Biology
|
November 24, 2025
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard Therapies
Stephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood
|
September 13, 2011
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Thomas O'Hare, Matthew S Zabriskie, Christopher A Eide, et al.
Cold Spring Harbor Molecular Case Studies
|
October 28, 2022
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia
Mara W Rosenberg, Samantha L Savage, Christopher A Eide, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2015
The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I
Julia E Maxson, Samuel B Luty, Jason D MacManiman, et al.
Cancer Research
|
April 21, 2011
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile
Christopher A Eide, Lauren T Adrian, Jeffrey W Tyner, et al.
Nature Genetics
|
December 22, 2005
Mutations in the CEL VNTR cause a syndrome of diabetes and pancreatic exocrine dysfunction
Helge Raeder, Stefan Johansson, Pål I Holm, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie
|
February 3, 2026
International validation of a staging system for ciliary body and choroidal melanomas using estimated tumour volume
Sacha Nahon-Estève, Jean-Pierre Caujolle, Célia Maschi, et al.
Page
of 12